Melatonin and the cardiovascular system in animals: systematic review and meta-analysis

Carregando...
Imagem de Miniatura
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
VEIGA, Eduardo Carvalho de Arruda
CAVIOLA, Leonardo L.
ABREU, Luiz Carlos
CAVALLI, Ricardo Carvalho
CIPOLLA-NETO, Jose
Citação
CLINICS, v.76, article ID e2863, 13p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Melatonin, a hormone released by the pineal gland, demonstrates several effects on the cardiovascular system. Herein, we performed a systematic review and meta-analysis to verify the effects of melatonin in an experimental model of myocardial infarction. We performed a systematic review according to PRISMA recommendations and reviewed MEDLINE, Embase, and Cochrane databases. Only articles in English were considered. A systematic review of the literature published between November 2008 and June 2019 was performed. The meta-analysis was conducted using the RevMan 5.3 program provided by the Cochrane Collaboration. In total, 858 articles were identified, of which 13 were included in this review. The main results of this study revealed that melatonin benefits the cardiovascular system by reducing infarct size, improving cardiac function according to echocardiographic and hemodynamic analyses, affords antioxidant effects, improves the rate of apoptosis, decreases lactate dehydrogenase activity, enhances biometric analyses, and improves protein levels, as analyzed by western blotting and quantitative PCR. In the meta-analysis, we observed a statistically significant decrease in infarct size (mean difference [MD],-20.37 [-23.56,-17.18]), no statistical difference in systolic pressure (MD,-1.75 [-5.47, 1.97]), a statistically significant decrease in lactate dehydrogenase in animals in the melatonin group (MD,-4.61 [-6.83,-2.40]), and a statistically significant improvement in the cardiac ejection fraction (MD,-8.12 [-9.56,-6.69]). On analyzing potential bias, we observed that most studies presented a low risk of bias; two parameters were not included in the analysis, and one parameter had a high risk of bias. Melatonin exerts several effects on the cardiovascular system and could be a useful therapeutic target to combat various cardiovascular diseases.
Palavras-chave
Cardiology, Melatonin, Meta Analysis, Review, Systematic Review
Referências
  1. Adriaenssens P, 1996, TIJDSCHR KIND
  2. Baltatu OC, 2017, CELL MOL LIFE SCI, V74, P3955, DOI 10.1007/s00018-017-2613-y
  3. Benova TE, 2019, MOL CELL BIOCHEM, V454, P191, DOI 10.1007/s11010-018-3463-0
  4. Chaudagar KK, 2016, PHYSIOL RES, V65, pS109, DOI 10.33549/physiolres.933400
  5. Chen WR, 2018, CELL PHYSIOL BIOCHEM, V47, P2067, DOI 10.1159/000491474
  6. Chen ZY, 2009, J PINEAL RES, V46, P235, DOI 10.1111/j.1600-079X.2008.00654.x
  7. Cheng XW, 2015, MOL MED REP, V11, P99, DOI 10.3892/mmr.2014.2753
  8. Cipolla-Neto J, 2018, ENDOCR REV, V39, P990, DOI 10.1210/er.2018-00084
  9. do Amaral FG, 2018, ARCH ENDOCRIN METAB, V62, P472, DOI 10.20945/2359-3997000000066
  10. Dominguez-Rodriguez A, 2014, INT J CARDIOL, V172, pE354, DOI 10.1016/j.ijcard.2013.12.303
  11. Dominguez-Rodriguez A, 2012, REV ESP CARDIOL, V65, P215, DOI [10.1016/j.rec.2011.10.011, 10.1016/j.recesp.2011.10.009]
  12. Dominguez-Rodriguez A, 2010, J PINEAL RES, V49, P14, DOI 10.1111/j.1600-079X.2010.00773.x
  13. Drobnik J, 2013, J PHYSIOL PHARMACOL, V64, P737
  14. Drobnik J, 2011, J PHYSIOL PHARMACOL, V62, P29
  15. Dziegiel P, 2003, J PINEAL RES, V35, P183, DOI 10.1034/j.1600-079X.2003.00079.x
  16. Favero G, 2017, AGEING RES REV, V35, P336, DOI 10.1016/j.arr.2016.11.007
  17. Ferreira CD, 2010, REV ASSOC MED BRAS, V56, P715, DOI 10.1590/S0104-42302010000600024
  18. Hadi A, 2019, HORM METAB RES, V51, P157, DOI 10.1055/a-0841-6638
  19. Henderson VC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001489
  20. Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
  21. Liu LF, 2015, GENET MOL RES, V14, P7481, DOI 10.4238/2015.July.3.24
  22. Liu LF, 2014, EUR REV MED PHARMACO, V18, P3681
  23. Liu Y, 2018, REDOX BIOL, V18, P211, DOI 10.1016/j.redox.2018.07.007
  24. McSweeney JC, 2016, CIRCULATION, V133, P1302, DOI 10.1161/CIR.0000000000000381
  25. Paredes SD, 2014, HORM MOL BIOL CLIN I, V18, P79, DOI 10.1515/hmbci-2014-0016
  26. Park SY, 2010, J PINEAL RES, V48, P178, DOI 10.1111/j.1600-079X.2009.00742.x
  27. Petrosillo G, 2009, AM J PHYSIOL-HEART C, V297, pH1487, DOI 10.1152/ajpheart.00163.2009
  28. Repova-Bednarova K, 2013, PHYSIOL RES, V62, pS135, DOI 10.33549/physiolres.932592
  29. Rhodes KM, 2018, J CLIN EPIDEMIOL, V95, P45, DOI 10.1016/j.jclinepi.2017.11.025
  30. Rodella LF, 2013, AGE, V35, P103, DOI 10.1007/s11357-011-9336-z
  31. Salmanoglu DS, 2016, REDOX BIOL, V8, P199, DOI 10.1016/j.redox.2015.11.007
  32. Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.i4086, 10.1016/j.ijsu.2010.02.007]
  33. Sharma S, 2015, ARCH ENDOCRIN METAB, V59, P391, DOI 10.1590/2359-3997000000098
  34. Simko F, 2018, MOLECULES, V23, DOI 10.3390/molecules23020265
  35. Simko F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081612
  36. Stacchiotti A, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121323
  37. Sun H, 2016, CURR OPIN LIPIDOL, V27, P408, DOI 10.1097/MOL.0000000000000314
  38. Tawfik GM, 2019, TROP MED HEALTH, V47, DOI 10.1186/s41182-019-0165-6
  39. Tordjman S, 2017, CURR NEUROPHARMACOL, V15, P434, DOI 10.2174/1570159X14666161228122115
  40. Zhang WX, 2019, LIFE SCI, V217, P8, DOI 10.1016/j.lfs.2018.11.055
  41. Zhu P, 2015, J CELL MOL MED, V19, P2232, DOI 10.1111/jcmm.12610
  42. Zorzela L, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i157